Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Operations (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Cash from Operations for 4 consecutive years, with 19316000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Operations fell 72.3% year-over-year to 19316000.0, compared with a TTM value of 67390000.0 through Dec 2023, down 37.23%, and an annual FY2024 reading of 70016000.0, down 3.9% over the prior year.
  • Cash from Operations was 19316000.0 for Q4 2023 at Terns Pharmaceuticals, up from 20699000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6313000.0 in Q3 2020 and bottomed at 20699000.0 in Q3 2023.
  • Average Cash from Operations over 4 years is 11758437.5, with a median of 11186500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 96.46% in 2021, then increased 7.1% in 2022.
  • Year by year, Cash from Operations stood at 7387000.0 in 2020, then tumbled by 44.43% to 10669000.0 in 2021, then decreased by 5.08% to 11211000.0 in 2022, then crashed by 72.3% to 19316000.0 in 2023.
  • Business Quant data shows Cash from Operations for TERN at 19316000.0 in Q4 2023, 20699000.0 in Q3 2023, and 12993000.0 in Q2 2023.